Please login to the form below

Not currently logged in
Email:
Password:

Warner Chilcott buy P&G's pharma business

Warner Chilcott, the speciality pharmaceuticals company, is to acquire Proctor & Gamble's portfolio of branded pharmaceutical products

Warner Chilcott, the speciality pharmaceuticals company, is to acquire Proctor & Gamble's portfolio of branded pharmaceutical products.

The porfolio of products involved in the acquisition includes Asacol HD (mesalamine), Actone (risedronate sodium) and the co-promotion rights to Enablex (darifenacin), as well as Proctor & Gamble's (P&G) prescription drug product pipeline and manufacturing facilities in Puerto Rico and Germany. Of the 2,300 employees at P&G's pharmaceuticals business, the majority are expected to transfer to Warner Chilcott.

The transaction – for $3.1bn – is likely to close by the end of 2009, pending necessary regulatory approvals. 

Said Roger Boissonneault, president and chief executive officer of Warner Chilcott: "The acquisition transforms Warner Childcott into a global pharmaceutical company, expands our presence in women's healthcare, establishes us in the urology market in advance of the anticipated launch of our erectile dysfunction treatments, and adds gastroenterology therapies to our product portfolio."

P&G said that it believes Warner Chilcott will be a strong investor in P&G's pharmaceutical assets, brands and capabilities and that the move will enable them to "focus singularly on winning in consumer health care".

24th August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics